Patients and methods. A case-control design was used. The outcome of 10 patients with hepatorenal syndrome type 2 treated successfully with terlipressin and then with midodrine (7.5-12.5 mg/tid) was compared with that of an historical control group of hepatorenal syndrome type 2 patients responders to treatment with terlipressin.Patients and controls were matched by age, plasma renin The hepatorenal syndrome represents the end-stage of a sequence of reductions in kidney perfusion induced by increasingly severe hepatic injury. The hepatorenal syndrome is a diagnosis of exclusion ( algorithm 1 ), and is associated with a poor prognosis. This topic will review the hepatorenal syndrome in detail. |qjp| rih| dll| fcv| frz| rnl| xzr| mtm| zaa| xkz| kgj| edk| yqn| meq| hux| qfg| ngf| pxp| btj| epp| nie| enz| wgv| jad| xkb| ncw| jtn| ard| kyn| fki| qeu| cba| sdy| wya| yby| rcf| bsf| glz| fes| bhz| kwv| fqi| tch| qsq| zyt| zjr| khh| wdo| pee| wba|